Stifel Financial Corp Buys 7,060 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Stifel Financial Corp lifted its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 10.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 72,194 shares of the medical instruments supplier’s stock after purchasing an additional 7,060 shares during the quarter. Stifel Financial Corp’s holdings in LeMaitre Vascular were worth $6,706,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in LMAT. NBC Securities Inc. grew its holdings in LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 183 shares during the last quarter. West Oak Capital LLC bought a new stake in LeMaitre Vascular during the 2nd quarter worth approximately $58,000. USA Financial Formulas bought a new stake in LeMaitre Vascular during the 3rd quarter worth approximately $60,000. nVerses Capital LLC grew its holdings in LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after acquiring an additional 200 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in LeMaitre Vascular by 34.3% during the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 188 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.79% of the stock is owned by insiders.

Analysts Set New Price Targets

LMAT has been the topic of a number of research reports. JMP Securities boosted their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Barrington Research upped their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Stock Up 0.4 %

Shares of NASDAQ LMAT opened at $100.69 on Friday. The firm has a market cap of $2.26 billion, a PE ratio of 55.02, a P/E/G ratio of 2.47 and a beta of 0.93. LeMaitre Vascular, Inc. has a 12-month low of $52.88 and a 12-month high of $109.58. The company’s fifty day simple moving average is $97.47 and its 200 day simple moving average is $89.33.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular’s revenue was up 15.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.33 earnings per share. On average, equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.64%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is presently 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.